[Market Focus] LG Chem Rises on Challenge to Develop Innovative Anticancer Drug

LG Chem is showing strong performance following news that the company is embarking on the development of innovative anticancer drugs targeting uncharted targets.

As of 9:18 a.m. on April 2, 2026, LG Chem is trading at 325,000 won, up 12,500 won (4.00%) compared to the previous day.

The previous day, LG Chem announced that it had signed a global exclusive development and commercialization license agreement with U.S.-based Frontier Medicines for "FMC-220," a novel anticancer drug candidate that is about to enter Phase 1 clinical trials.

FMC-220 is a "p53 Y220C activator" that works by restoring the original function of p53 in cases where the "Y220C mutation" occurs among several mutations of the uncharted tumor suppressor protein "p53." The p53 Y220C mutation is one of the key targets, found in approximately 1-3% of all cancer patients. Until now, it has been considered an "undruggable" target due to structural constraints of the protein, making drug development difficult.

LG Chem plans to initially develop the drug for ovarian cancer, where the prevalence of the p53 Y220C mutation is relatively high, and then expand its indications to various solid tumors.

This content was produced with the assistance of AI translation services.